Australian biopharma Immutep Ltd. saw its stock price jump 165% Dec. 10, as the company reported that adding its eftilagimod alpha (IMP-321, “efti”) to paclitaxel resulted in what the company called a “promising and improving” trend toward increased overall survival in women with metastatic hormone receptor-driven breast cancer.
SHENZHEN, China – Ever since Chinese President Xi Jinping visited Shenzhen in October, the southern city has been tasked with developing itself into an innovation powerhouse. Biotech veterans now see Shenzhen, designated China’s first special economic zone in 1980 and a symbol of its opening up, as a biotech innovation hub that will take Chinese innovation overseas.
SHENZHEN – While China is rather new in biotech innovation and still has potential for growth, industry insiders worry about the long-term sustainability of innovation. Speaking at a recent conference in the southern Chinese city of Shenzhen, various experts said sustaining innovation may depend on differentiation, globalization and reimbursement policies.
SHENZHEN – To accelerate the development of cell therapies, China’s NMPA has introduced a dual-track regulatory pathway that allows companies to seek an IND with data from investigator-initiated trials.
The Chinatrials roundtable went virtual this year and drew clinical trial experts to discuss state-of-the-art clinical trial design strategies, which are increasingly important in a more competitive clinical landscape.
RSS
